MediciNova, Inc. (MNOV)
| Market Cap | 70.63M +7.5% |
| Revenue (ttm) | 920,481 +583.9% |
| Net Income | -10.75M |
| EPS | -0.22 |
| Shares Out | 49.22M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 16,884 |
| Open | 1.420 |
| Previous Close | 1.420 |
| Day's Range | 1.420 - 1.449 |
| 52-Week Range | 1.168 - 1.960 |
| Beta | 0.62 |
| Analysts | Strong Buy |
| Price Target | 9.00 (+527.18%) |
| Earnings Date | Aug 13, 2026 |
About MNOV
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute res... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for MNOV stock is "Strong Buy." The 12-month stock price target is $9.0, which is an increase of 527.18% from the latest price.
News
MediciNova Quarterly report: Q2 2026
MediciNova has published its Q2 2026 quarterly earnings report on August 13, 2026.
MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients
LA JOLLA, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange ...
MediciNova CEO Provides Shareholder Update
LA JOLLA, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange ...
MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment
LA JOLLA, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (...
MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
LA JOLLA, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (...
MediciNova Slides: Corporate presentation
MediciNova has posted slides in relation to its latest quarterly earnings report, which was published on May 26, 2026.
MediciNova Quarterly report: Q1 2026
MediciNova has published its Q1 2026 quarterly earnings report on May 14, 2026.
MediciNova Proxy statement: Proxy filing
MediciNova filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
MediciNova Proxy statement: Proxy filing
MediciNova filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
MediciNova’s peer-reviewed ibudilast study advances clinical translation
The company states: “MediciNova (MNOV) and the Standard Market of the Tokyo Stock Exchange announced that a study conducted by researchers at the Spanish National Cancer Research Centre has identified...
New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation
LA JOLLA, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange...
MediciNova Proxy statement: Proxy filing
MediciNova filed a proxy statement on April 20, 2026, providing details for shareholder voting and corporate governance matters.
MediciNova Proxy statement: Proxy filing
MediciNova filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Maxim resumes MediciNova at Buy on potential value-driving data events this year
Maxim analyst Michael Okunewitch resumed coverage of MediciNova (MNOV) with a Buy rating and $6 price target The firm is positive on the company’s potential value-driving data events in 2026,…
MediciNova resumed with a Buy at Maxim
Maxim resumed coverage of MediciNova (MNOV) with a Buy rating and $6 price target
MediciNova to Participate at the 38th Annual ROTH Conference
LA JOLLA, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange...
MediciNova initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of MediciNova (MNOV) with a Buy rating and $10 price target MediciNova is a clinical-stage biotechnology company developing multi-target small molecule therapies acr...
MediciNova management to meet with Maxim
Meeting to be held on February 26 hosted by Maxim.
MediciNova Annual report: Q4 2025
MediciNova has published its Q4 2025 annual report on February 20, 2026.
MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients
LA JOLLA, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (...
MediciNova issues letter to shareholders
MediciNova (MNOV) provides shareholders a corporate update in the following Letter to Stockholders from CEO Yuichi Iwaki, M.D., Ph.D. “The year 2025 was marked by global uncertainty, with accelerating...
2026 New Year's Greetings from the CEO
LA JOLLA, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Standard Market of the Tokyo Stock Exchange (...
MediciNova initiated with a Buy at Lucid Capital
Lucid Capital analyst Elemer Piros initiated coverage of MediciNova (MNOV) with a Buy rating and $11 price target The firm says the company is in a pivotal trial with an…
MediciNova completes patient enrollment in neuropathy trial of MN-166
MediciNova (MNOV) completed patient enrollment in the Phase 2 clinical trial, the OXTOX study – Oxaliplatin Neurotoxicity study in patients with metastatic colorectal cancer -. This study is evaluatin...
MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy
LA JOLLA, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (...